TO MARKET, TO MARKET–2022: SMALL MOLECULES-Reference-Cited by-同舟云学术

TO MARKET, TO MARKET–2022: SMALL MOLECULES

Published:2023-11-16 Issue: Volume: Page:595-710
ISSN:2575-9183
Container-title:Medicinal Chemistry Reviews
language:
Short-container-title:

Author:

Araujo Erika¹,Bell Ian M.²,Burckle Alexander³,Koester Dennis C.⁴,Manning James R.⁵,Castanedo Georgette,Zeng Mingshuo,Murali Dhar T. G.⁶,Holmberg-Douglas Natalie,Welin Eric R.,Merritt J. Robert⁷,Peese Kevin M.⁸,Bronson Joanne J.⁹

Affiliation:

1. Arvinas, New Haven, Connecticut, U.S.A.

2. Merck, West Point, Pennsylvania, U.S.A.

3. Gilead Sciences, Foster City, California, U.S.A.

4. FibroGen, San Francisco, California, U.S.A.

5. Novartis Institutes for BioMedical Research, Emeryville, California, U.S.A.

6. Bristol Myers Squibb, Princeton, New Jersey, U.S.A.

7. Genesis Biotechnology Group, Hamilton, New Jersey, U.S.A.

8. ViiV Healthcare, Branford, Connecticut, U.S.A.

9. Bristol Myers Squibb, Cambridge, Massachusetts, U.S.A.

Publisher

MEDI, Inc. Published by American Chemical Society.

Link

https://pubs.acs.org/doi/pdf/10.1021/mc-2023-vol58.ch24

Reference334 articles.

1. TO MARKET, TO MARKET–2021: SMALL MOLECULES

2. 2022 FDA approvals

3. FDA Website. Novel Drug Approvals for 2022.https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2022(accessed January 12, 2023).

4. FDA Website. Accelerated Approval of Adagrasib.https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-adagrasib-kras-g12c-mutated-nsclc(accessed May 11, 2023).

5. FDA Website. Krazati™ Prescribing Information.https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340s000lbl.pdf(accessed May 11, 2023).